Arnon Rosenthal received his Ph.D. from the Hebrew University Jerusalem, Israel. He then went on to Genentech, Inc., becoming a staff scientist and a permanent member of the Genentech Research Review Committee in 1996. Over the course of his career, Rosenthal has co-founded multiple companies aimed at developing novel therapeutics for neurodegenerative, neuroendocrine and pain disorders, resulting in over 100 scientific publications and over 380 patent applications.

Rosenthal developed several drugs in clinical development as a co-founder and CSO of Rinat Neuroscience, a company since acquired by Pfizer. Rinat Neuroscience initiated the development of Tanezumab, which is currently in Phase III for multiple pain indications; PF-04360365, which entered Phase II for Alzheimer’s disease; and RN-307, which entered the clinic for migraine. Rosenthal is actively involved in two additional companies he co-founded, Annexon Biosciencs and Alector, LLC, whose goals are to develop and assess novel drug targets and therapies for the treatment of Alzheimer’s disease and other forms of dementia. Rosenthal is also currently a visiting professor at University of California, San Francisco, in the department of anatomy.

In addition to his role on the SFARI scientific advisory board, Rosenthal is on the scientific advisory board for the Myelin Repair Foundation.